Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRMakoto Maemondo, Toshihiro Nukiwa, Shoji Okinaga et al.|New England Journal of Medicine|2010Cited by 5.6k
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trialHaruhiro Saito, Makoto Maemondo, Tatsuro Fukuhara et al.|The Lancet Oncology|2019Cited by 636
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 StudyYukio Hosomi, Satoshi Morita, Shunichi Sugawara et al.|Journal of Clinical Oncology|2019Cited by 483
A cross-validation of the European organization for research and treatment of cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with Lung CancerKunihiko Kobayashi, Kiyokazu Yoshida, Fumikazu Takeda et al.|European Journal of Cancer|1998Cited by 255
Mutations in the <i>SLC34A2</i> Gene are Associated with Pulmonary Alveolar MicrolithiasisHuqun, Koichi Hagiwara, Shinyu Izumi et al.|American Journal of Respiratory and Critical Care Medicine|2006Cited by 196